CanBas Co., Ltd. (TYO:4575)

Japan flag Japan · Delayed Price · Currency is JPY
1,013.00
-22.00 (-2.13%)
Jul 16, 2025, 3:30 PM JST
68.83%
Market Cap19.36B
Revenue (ttm)n/a
Net Income (ttm)-1.49B
Shares Out19.11M
EPS (ttm)-79.96
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume168,500
Average Volume528,045
Open1,027.00
Previous Close1,035.00
Day's Range1,012.00 - 1,033.00
52-Week Range432.00 - 1,512.00
Beta-1.28
RSI49.58
Earnings DateAug 8, 2025

About CanBas

CanBas Co., Ltd., a clinical stage biopharmaceutical company, develops therapeutics for cancer patients. It develops CBP501, a calmodulin-modulating peptide to treat various cancer; and CBS9106, a reversible exportin-1inhibitor that is in Phase I clinical trial for the treatment of solid tumors. The company has a collaboration alliance with Stemline Therapeutics, Inc. CanBas Co., Ltd. was incorporated in 2000 and is based in Numazu, Japan. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2000
Employees 11
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4575
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.